Skip to main content
. 2021 May 31;13(11):2734. doi: 10.3390/cancers13112734

Figure 2.

Figure 2

IHC on tissues from captopril treated and control mice. Fixed tissue sections (control, n = 9 and captopril, n = 10) were stained for the indicated proteins. Captopril treatment was associated with a significant reduction of (A) c-myc IHC detection in both the liver (p = 0.0185) and tumor (p = 0.0218) and a significant increase in (F) β-catenin IHC detection within tumor (p = 0.0302). Captopril was not associated with any significant changes in (B) Ki67 IHC detection for either liver (p = 0.3897) or tumor (p = 0.6071), (C) Cyclin D1 IHC detection for either liver (p = 0.4397) or tumor (p = 0.3713), (D) E-Cadherin IHC detection for either liver (p = 0.5041) or tumor (p = 0.3148), (E) Vimentin IHC detection for either liver (p = 0.9818) or tumor (p = 0.6011) or β-catenin IHC detection in liver (p = 0.0847). Unpaired, two tailed t-test. * p < 0.05.